Home » Izana Begins Trial of Rheumatoid Arthritis Drug for COVID-19
Izana Begins Trial of Rheumatoid Arthritis Drug for COVID-19
Izana Bioscience has initiated a two-center compassionate use study of its drug namilumab for treatment of patients with rapidly worsening COVID-19.
Namilumab is a human monoclonal antibody therapy that targets granulocyte-macrophage colony stimulating factor. It is currently in late-stage clinical development for the treatment of rheumatoid arthritis and ankylosing spondylitis.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May